Video

Our team behind the scenes at SXSW | Building a Disease Specific Knowledge Base

In part two of our SXSW series, our team shows how we use AI and machine learning to better understand specific diseases - in this case, Glioblastoma (GBM), the most common and aggressive form of brain cancer.

Given the complexity of a savage disease like GBM, a scientist alone could not read up on all the research that has been done to understand it. At BenevolentAI, we have developed a biomedical knowledge base to contextualise all the relevant information and relationships between diseases, genes, drugs and other important research that has already been published.

Our knowledge graph pulls out all the relevant links to ongoing and completed clinical trials, existing compounds that have been tested against the disease, and the underlying biological connections known to be associated with the disease. Together, these biological facts represent all that is known to be true about a disease today.

Our technology platform helps us understand diseases like GBM by sitting on top of this knowledge base and answering two fundamental questions, i) what do we know about the disease today? and ii) where are the gaps in that knowledge base?


Watch our team demonstrate how algorithms can analyse this knowledge and reason across it to provide scientists and researchers with capabilities beyond human insight.

More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021